Gout Market Analysis

Global Gout Market Overview

Gout Market size was valued at USD 4.57 billion in 2022. The gout market industry is projected to grow from USD 5.07 billion in 2023 to USD 11.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.75% during the forecast period (2023 - 2032).

Increasing prevalence of gout is driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In February 2024, the leading national pharmacy chain starts selling GLOPERBA® in most of its stores countrywide. Scilex is also in talks to have similar potential stocking arrangements with other pharmacies across the United States. The third-party logistics firm for Scilex, Cardinal Health, can provide commercial product inventory of GLOPERBA® that may be needed upon its expected first-half-2024 launch.

GLOPERBA® became the first and remains the only oral liquid form of colchicine used as a prophylactic against adult gout flares. This painful arthritic condition affects approximately 9.2 million Americans. As a result of the increasing prevalence of gout every year, treatment demand increases with it. The data from Evaluate Pharma has projected that by 2028, the gout treatment market will reach $2B in the US with well-defined unmet need area².

April 2024 is when Veganuary responds to growing fears about avian flu and sustainability by introducing Choose Chicken-Free Week. The goal behind this program is to show how easy it is to replace chicken or eggs with plant-based alternatives. It coincides with Respect for Chickens Day and extends from April 29 through May 5, featuring more than enough resources like recipes and tips on Veganuary’s website. However, Veganuary does not limit itself to only January but offers support throughout the year for individuals as well as working together with companies to increase plant-based food options. Choose Chicken-Free Week is an example of how veganism continues to grow.

Scilex Holding Company (Nasdaq: SCLX) (“Scilex” or “Company”), an innovative revenue-generating company engaged in acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment, announced that it recently completed Gloperba®, a prophylactic drug approved by FDA meant specifically for adults who are suffering from painful gout flares in the US, commercial manufacturing and Gloperba® which it expects to launch within the first quarter of 2024 in the US. It is yet another commercial asset that complements this Company’s portfolio and enables them to arm physicians with one more non-narcotic analgesic for earlier use in patients’ journey as they keep working on redefining opioids to be the last-resort rescue medication against gout.

Gout Market Trends

• Increasing prevalence of gout to boost the growth of the market.

Gout is a type of inflammatory arthritis that affects men over the age of 40, who have a high amount of uric acid in their blood. According to studies, its prevalence and incidence have increased in the last few decades. The rising prevalence of gout due to changing lifestyle patterns and the growing geriatric population is expected to boost market growth over the forecast period. For instance, as per the article published by the Annals of Rheumatic Diseases in June 2021, a nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021 observed that the prevalence rate of gout has increased from 0.98%in 1997 to 2.33% in 2021. However, according to the same source, the incidence of gout increased by 0.98/1,000 persons in UK 2021. Therefore, the burden of gout is expected to increase the demand for drugs treating this condition, which is anticipated to propel the market growth over the forecast period.

Gout Market Segment Insights

Gout Technology Insights

The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. The treatment segment is to hold the majority share in 2022 in the Gout Market revenue due to treatment segment includes different drugs namely NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. Non-steroidal anti-inflammatory drugs are members of a therapeutic drug class that reduces pain, inflammation, fever, and blood clots. Corticosteroids, also known as steroids, are anti-inflammatory medications used to treat a variety of conditions. Colchicine is used to prevent gout attacks in adults (abnormally high levels of a substance called uric acid in the blood cause sudden, severe pain in one or more joints).  Urate-lowering therapies for gout are broadly classified as xanthine oxidase inhibitors (allopurinol and febuxostat), uricosuric agents (benzbromarone and probenecid), and recombinant uricases.

April 2019: The U.S. Food and Drug Administration (FDA) has approved GLOPERBA (colchicine) to treat adult gout flare-ups.

Gout Application Insights

The Gout Market segmentation is based on applications that include acute gout and chronic gout. The acute gout segment has dominated the market in 2022 due to the Acute gout attacks are distinguished by their rapid onset and progression, with joint pain typically peaking within 24 hours of the attack's onset. Without intervention, an acute attack usually begins to fade after 5 to 12 days, but complete resolution may take longer in some patients. Furthermore, non-steroidal anti-inflammatory drugs or corticosteroids are used as first-line therapy for acute gout, depending on comorbidities; colchicine is used as second-line therapy.

March 2020: Horizon Therapeutics plc launched Down and Out Kidney, an operation to feature the damaging effects combined with the collection of uric acid and gout in patients with chronic kidney disease (CKD).

FIGURE 2: Gout Market, By Application, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Gout End User Insights

The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others. The hospitals & clinics segment have dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period, 2023- 2032. This is due to the availability of better medical facilities, proficient medical staff, and large number of patient pool. A doctor or a team of doctors who specialize in the care of gout patients should diagnose and treat the disease. This is significant because the signs and symptoms of gout are not specific and can resemble those of other inflammatory diseases. Rheumatologists are doctors who specialize in gout and other types of arthritis. For instance, according to a study conducted by NCBI, up to 18% of gout patients are hospitalized each year (all causes), making hospitalization an important potential exposure at the population level.

March 2022: Atom Bioscience reported the progressive results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.

Gout Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

The North America region segmented into US, and Canada. The North America region held the largest market share in the Gout Market and market is accounted for USD 1.80 billion in 2022 and is expected to exhibit a 12.03% CAGR during the study period. Further, in the North America region the US gout market accounted for the largest market share. This is attributed to the increasing prevalence of gout, growing adoption of biologics, and rising R&D activities on regenerative medicines. Moreover, the growing awareness about the health & accessibility of new treatment methods, the presence of well-developed healthcare infrastructure, and the rapid adoption of advanced medical technologies in the region drive the regional market growth during the forecast period.

In 2021, as per the Journal of the American Medical Association (JAMA) Network, an estimated 9.2 million people are affected by gout in the US, and it is more common in men and older people. The rising prevalence of gout demands effective treatment such as NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others for treating this condition. In addition, the rising product launches are also contributing to market growth over the forecast period.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Gout Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe gout market is expected to account for the second-largest market share due to the accessibility to advanced diagnosis & treatment facilities, the rising geriatric population prone to gout is driving up demand for effective treatment & therapeutics, and growing healthcare expenditure. For instance, according to the Eurostat database, healthcare expenditure was USD 176.61 billion in 2021.

Owing to rising healthcare expenditure also increases the company activities and government initiatives in developing effective diagnoses and treatment & therapeutics for gout, the Italy gout market is expected to be fastest growing market in the European region, followed by UK gout market. These factors are anticipated to positively impact the growth of the gout market. Additionally, improving government initiatives & healthcare frameworks and the presence of government organizations are boosting the growth of the gout market in Europe.

The Asia-Pacific gout market is expected to grow at a CAGR of 13.12% from 2023 to 2032. This is due to factors such as improving healthcare infrastructure, growing investment by major players with local manufacturers, and the increasing patient population suffering from gout. For instance, according to the Australian Bureau of Statistics, in 2018, an estimated 4.5% of Australians have gout. Gout is more common in males than females almost 8 in 10 (79%) people with gout are males. Hence, the rise in patients suffering from gout drives the market growth in the region as gout medications such as allopurinol, febuxostat, and probenecid among others are extensively used to reduce uric acid levels in the blood. This can help reduce the number of future flares and make them less severe. Additionally, the availability of technical expertise, reduced cost of labor, and funding from governments for R&D investment to accelerate new product development have made Asia-Pacific the most favored region for outsourcing manufacturing services.

The Rest of the World includes the Middle East, Africa, and Latin America. Middle East hold the major market share in middle east and Africa region due to limited healthcare infrastructure, a dearth of awareness regarding the symptoms of the disease, and a lack of skilled professionals to manufacture gout therapeutics drugs are restricting the growth of the gout market in Sub-Saharan Africa. Additionally, low healthcare expenditure and unstable political situations are also affecting the market growth to an extent in the Middle East. However, growing healthcare infrastructure, increasing government initiatives for improving the healthcare sector, and the growing geriatric population in the Middle East region are likely to favor market growth.

Gout Key Market Players & Competitive Insights

The Gout Market is distinguished by the presence of numerous global, regional, and local players catering to the increasing prevalence of gout, rising healthcare expenditure, and increasing research and development activities. However, the side effects of gout therapeutic drugs and the lack of awareness among people may hamper the growth of the Gout Market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products to broaden their reach.

The Gout Market is extremely competitive, with players competing, partnering, and investing heavily in research and development to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.

The business model developed by manufacturers in the Gout Market includes offering high-quality products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key players in the gout market are focusing on offering high-quality products to their customers. It is also projected that a rising number of strategic initiatives will boost the market's growth in the upcoming future.

Key Companies in the Gout Market Include.

• Novartis AG (Switzerland)


• Lannett (US)


• Horizon Therapeutics plc (US)


• Takeda Pharmaceutical Company Limited (Japan)


• GlaxoSmithKline plc (UK)


• Regeneron Pharmaceuticals, Inc (US)


• Teijin Limited (Japan)


• Viatris Inc (US)


• Boehringer Ingelheim International GmbH (Germany)


• ROMEG Therapeutics, LLC (US)

Gout Industry Developments

March 2023: Selecta Biosciences, Inc revealed positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is used for chronic refractory gout.

July 2022: The company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

July 2022: ROMEG Therapeutics, LLC (US) and Scilex Holding Company (US) enters into an agreement for an exclusive license to market Gloperba, an FDA-approved preventative medication for excruciating gout flare-ups in adults, in the US.

April 2019: The U.S. Food and Drug Administration (FDA) has approved GLOPERBA (colchicine) to treat adult gout flare-ups.

March 2022: the United States Food and Drug Administration approved Strides Pharma's Colchicine tablets USP, 0.6 mg, used for the treatment and prevention of gout.

Gout Market Segmentation

Gout Treatment and Diagnosis Outlook

• Diagnosis


• Treatment
  
  
  
  • NSAIDs
  
  
  • Corticosteroids
  
  
  • Colchicine
  
  
  • Urate-Lowering Agents
  
  
  • Others
  
  
  
  

Gout Application Outlook

• Acute Gout


• Chronic Gout

Gout End User Outlook

• Hospitals & Clinics


• Specialty Centers


• Others

Gout Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East and Africa
  
  
  
  • Middle East
  
  
  • Africa